{"id":"celsior-group","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL2108795","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by activating the glucagon receptor, which increases glucose levels in the bloodstream, and is being investigated for the treatment of hypoglycemia in patients with type 1 diabetes.","oneSentence":"CELSEOR is a glucagon receptor agonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:50:37.450Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypoglycemia for prevention in patients with type 1 diabetes"}]},"trialDetails":[{"nctId":"NCT06717919","phase":"PHASE4","title":"HOPE Against Cancer Recurrence in HCC","status":"RECRUITING","sponsor":"Philipp Dutkowski","startDate":"2025-08-01","conditions":"Liver Transplantation, HCC, Oncological Outcomes","enrollment":220},{"nctId":"NCT04616222","phase":"","title":"A Retrospective Comparison of the Efficacy and Safety of Celsior® in Pediatric Cardiac Surgery for Transposition of the Great Vessels","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"2020-09-01","conditions":"Transposition of Great Vessels","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CELSIOR® group","genericName":"CELSIOR® group","companyName":"Hospices Civils de Lyon","companyId":"hospices-civils-de-lyon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CELSEOR is a glucagon receptor agonist. Used for Hypoglycemia for prevention in patients with type 1 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}